Finance

Beta
Lists
SBHMY:OTCMKTS
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
$11.27
-6.36%
(-0.76) 1D
Jun 11, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SBHMY...
Open
$11.27
High
$11.27
Low
$11.27
Mkt. cap
87.91B
Avg. vol.
10.00
Volume
189.00
52-wk high
$20.16
52-wk low
$11.27
Beta
0.38
Shares outstanding
935.25M
No. of employees
21K
Open
$11.27
High
$11.27
Low
$11.27
Mkt. cap
87.91B
Avg. vol.
10.00
Volume
189.00
52-wk high
$20.16
52-wk low
$11.27
Beta
0.38
Shares outstanding
935.25M
No. of employees
21K
News stories
From sources across the web
Profile
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Unsponsored Caymand Islands ADR
CEOLi Yi
Employees21.4K
Founded2000
Headquarters-
SectorPharmaceutical industry
Websitesbpgroup.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
8.79B
8.79B
7.13B
7.13B
Cost of goods sold
1.54B
1.54B
1.31B
1.31B
Cost of revenue
1.54B
1.54B
1.31B
1.31B
Research and development expenses
-
-
2.93B
2.93B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.77B
3.77B
2.80B
2.80B
Operating expense
5.54B
5.54B
4.38B
4.38B
Total operating expenses
7.08B
7.08B
5.69B
5.69B
Operating income
1.70B
1.70B
1.44B
1.44B
Other non operating income
40.54M
40.54M
97.99M
97.99M
EBT including unusual items
2.98B
2.98B
488.22M
488.22M
EBT excluding unusual items
2.72B
2.72B
1.55B
1.55B
Income tax expense
490.66M
490.66M
323.77M
323.77M
Effective tax rate
16.45%
16.45%
66.32%
66.32%
Other operating expenses
1.77B
1.77B
-1.35B
-1.35B
Net income
1.69B
1.69B
-522.62M
-522.62M
Net profit margin
19.28%
19.28%
-7.33%
-7.33%
Earnings per share
-
-
-
-
Interest and investment income
989.64M
989.64M
196.36M
196.36M
Interest expense
-61.60M
-61.60M
-77.56M
-77.56M
Net interest expenses
928.03M
928.03M
118.80M
118.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.97B
1.97B
1.66B
1.66B
Gain or loss from assets sale
-
-
-5.58M
-5.58M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer